SVT 1C469
Alternative Names: Live microbial biotherapeutic - Servatus Biopharmaceuticals; SVT-1C469Latest Information Update: 28 Oct 2023
At a glance
- Originator Servatus Biopharmaceuticals
- Class Antibacterials; Bacteria
- Mechanism of Action Gastrointestinal microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Helicobacter infections
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for phase-I development in Helicobacter-infections in Australia (PO)
- 23 Sep 2020 Phase-I clinical trials in Helicobacter infections in Australia (PO) (ACTRN12620000923965) (Servatus Biotherapeutics pipeline, September 2020)
- 17 Sep 2020 Servatus BioTherapeutics plans a phase I trial for Helicobacter pylori infections (Monotherapy) in October 2020 in Australia (PO) (ACTRN12620000923965)